Kymera Therapeutics
Kymera Therapeutics Inc is an American clinical-stage biopharmaceutical company focused on targeted protein degradation for immunology, inflammation, and oncology indications. The company utilizes its proprietary Pegasus technology platform to design small molecule degrader medicines that selectively remove disease-causing proteins. Principal revenue is derived from strategic research collaborations, licensing agreements, and milestone payments from global biopharmaceutical partners. Core end markets embrace immunology medical practices, oncology clinics, and specialized clinical research institutions globally. Kymera Therapeutics holds a pioneer position in the biopharmaceutical industry for targeted protein degradation drug candidate development. The company is headquartered in Watertown, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
8 of the funds FundTelligence covers report a position in Kymera Therapeutics.
- Legal name
- Kymera Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 8
Funds holding Kymera Therapeutics
- UBS Biotech Equity Fund — UBS · 2.6 % (largest positions only, September 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.7 % (full portfolio disclosed, October 2026)
- T. Rowe Price US Smaller Companies Equity Fund — T. Rowe Price · 0.63 % (full portfolio disclosed, September 2026)
- Schroder ISF Healthcare Innovation — Schroders · 0.49 % (full portfolio disclosed, June 2026)
- T. Rowe Price US Lrg Cap Gr Eq — T. Rowe Price · 0.19 % (full portfolio disclosed, September 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.08 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.05 % (partially disclosed portfolio, June 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)